FFA
PTCT icon

Farther Finance Advisors’s PTC Therapeutics PTCT Stock Holding History

Farther Finance Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.5K Buy
693
+142
+26% +$10.3K ﹤0.01% 3155
2026
Q1 		$37.9K Buy
551
+200
+57% +$14.2K ﹤0.01% 3200
2025
Q4 		$26.7K Buy
351
+128
+57% +$9.3K ﹤0.01% 3242
2025
Q3 		$13.7K Sell
223
-2,411
-92% -$126K ﹤0.01% 3270
2025
Q2 		$129K Buy
2,634
+2,622
+21,850% +$124K ﹤0.01% 1630
2025
Q1 		$559 Hold
12
– – ﹤0.01% 3754
2024
Q4 		$542 Sell
12
-3
-20% -$128 ﹤0.01% 3428
2024
Q3 		$557 Buy
15
+10
+200% +$335 ﹤0.01% 3400
2024
Q2 		$156 Buy
5
+3
+150% +$97 ﹤0.01% 3532
2024
Q1 		$57 Hold
2
– – ﹤0.01% 3455
2023
Q4 		$55 Sell
2
-1
-33% -$23 ﹤0.01% 3369
2023
Q3 		$67 Hold
3
– – ﹤0.01% 2560
2023
Q2 		$122 Hold
3
– – ﹤0.01% 2416
2023
Q1 		$145 Hold
3
– – ﹤0.01% 2253
2022
Q4 		$115 Buy
+3
New +$125 ﹤0.01% 2124

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Farther Finance Advisors's PTCT Position: Q2 2026 in Review

Farther Finance Advisors increased its PTC Therapeutics (PTCT) stake by 26% in Q2 2026, buying an estimated $10.3K and bringing the position to 693 shares worth $56.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3155.

Farther Finance Advisors first reported a position in PTCT in Q4 2022 and has held it in 15 quarters since. The position peaked at $129K in Q2 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Farther Finance Advisors held 693 shares of PTC Therapeutics worth $56.5K as of Q2 2026.
  • Farther Finance Advisors bought 142 PTC Therapeutics shares in Q2 2026, an estimated $10.3K.
  • PTC Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #3155 holding.
  • Farther Finance Advisors first reported a position in PTC Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Farther Finance Advisors's PTC Therapeutics position peaked at $129K in Q2 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.